Patents Assigned to The University of Texas System
  • Patent number: 11767564
    Abstract: Provided herein are methods for identifying expression of SDHA, MIF, and or monosomy 3 or disomy 3 status in sample to identify the sample as high-risk melanoma and/or the sensitivity to oxidative phosphorylation inhibitors. Also provided herein are methods for treating monosomy 3 uveal melanoma by administering a SDHA inhibitor in combination with an oxidative phosphorylation inhibitor.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: September 26, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Chandrani Chattopadhyay, Janos Roszik
  • Patent number: 11766402
    Abstract: Provided herein are methods of manufacturing clinical grade exosomes derived from mesenchymal stem cells (MSCs). Further provided are methods of loading the exosomes with therapeutic agents, such as siRNA. Also provided herein are methods of treating diseases by administering the clinical grade exosomes.
    Type: Grant
    Filed: November 16, 2018
    Date of Patent: September 26, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Elizabeth Shpall, Raghu Kalluri, Katy Rezvani, Mayela Mendt, Valerie Lebleu, Sushrut Kamerkar
  • Patent number: 11766408
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Grant
    Filed: March 4, 2021
    Date of Patent: September 26, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Qiang Cheng, Tuo Wei, Daniel J. Siegwart
  • Publication number: 20230295706
    Abstract: Aspects of the disclosure relate to compositions and methods for amplifying and/or detecting one or more target nucleic acid sequences (e.g., a nucleic acid sequence of one or more pathogens) in a biological sample obtained from a subject. In some embodiments, the pathogens are viral, bacterial, fungal, parasitic, or protozoan pathogens, such as SARS-CoV-2 or an influenza virus. In some embodiments, the methods comprise isothermal amplification of a target nucleic acid and subsequent detection of the amplification products.
    Type: Application
    Filed: January 12, 2023
    Publication date: September 21, 2023
    Applicants: Detect, Inc., Board of Regents, The University of Texas System
    Inventors: Spencer Glantz, Jonathan M. Rothberg, Xinghua Shi, Benjamin Rosenbluth, Jaymin Patel, William A. Hansen, Jonathan Naccache, Hope Kronman, Henry Kemble, Caixia Lv, Andrew Ellington, Sanchita Bhadra
  • Patent number: 11760799
    Abstract: Antibody antigen binding domains which specifically binds human leptin comprises VH or VL CDR1, CDR2 and CDR3 sequences of an hLept antibody. The antibody antigen binding domains and antibodies thereof are useful to treat obesity and diabetes.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: September 19, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Zhiqiang An, Ningyan Zhang, Philipp E. Scherer, Shangang Zhao
  • Patent number: 11762284
    Abstract: A method for fabricating patterns. An inverse optimization scheme is implemented to determine process parameters used to obtain a desired film thickness of a liquid resist formulation, where the liquid resist formulation includes a solvent and one or more non-solvent components. A substrate is covered with a substantially continuous film of the liquid resist formulation using one or more of the following techniques: dispensing discrete drops of a diluted monomer on the substrate using an inkjet and allowing the dispensed drops to spontaneously spread and merge, slot die coating and spin-coating. The liquid resist formulation is diluted in the solvent. The solvent is then substantially evaporated from the liquid resist formulation forming a film. A gap between a template and the substrate is then closed. The film is cured to polymerize the film and the substrate is separated from the template leaving the polymerized film on the substrate.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: September 19, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Sidlgata V. Sreenivasan, Shrawan Singhal, Ovadia Abed, Lawrence Dunn
  • Patent number: 11763451
    Abstract: The disclosure describes imaging and therapy techniques comprising nanodroplets. More particularly, aspects of the disclosure relate to the use of nanodroplets to modify nanobubbles or microbubbles to provide improved imaging and/or therapeutic techniques and compositions.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: September 19, 2023
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Robert F. Mattrey, Caroline De Gracia Lux, Jacques Lux, Zhenghong Gao, Carlos J. Brambila
  • Publication number: 20230285558
    Abstract: Embodiments of the disclosure encompass methods and compositions related to cell therapy treatment, including for cancer. In specific embodiments, the disclosure concerns adoptive cell therapy cancer treatment in which tumor-1 infiltrating lymphocytes and/or engineered T cells are modified to increase their efficacy as a cancer treatment. In specific cases, the cells are engineered for knock out of one or more genes, such as Signaling Threshold Regulating Transmembrane Adaptor 1 (SIT1), Bone Marrow Stromal Cell Antigen 2 (BST2), and/or programmed cell death protein 1 (PD-1).
    Type: Application
    Filed: July 23, 2021
    Publication date: September 14, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Patrick HWU, Barbara M. NASSIF RAUSSEO
  • Publication number: 20230288415
    Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
    Type: Application
    Filed: December 7, 2022
    Publication date: September 14, 2023
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Edward K. Wakeland, David E. Gerber, Quanzhen Li, Shaheen Khan, Saad Khan, Yang Xie, Jason Y. Park, Farjana Fattah, Xin Luo
  • Patent number: 11754778
    Abstract: A photoreactor including a reservoir configured to hold water, the reservoir defining an inlet and an outlet, and a multiplicity of optical fiber assemblies positioned in the reservoir. Each optical fiber assembly includes one or more optical fibers coated with a composition comprising a photoresponsive polymer and a light source optically coupled to the one or more optical fibers. The photoresponsive polymer undergoes a change from an initial state to an irradiated state when irradiated with light from the light source, and photoresponsive polymer in the irradiated state is adapted to bind an ion from the water.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: September 12, 2023
    Assignees: Arizona Board of Regents on behalf of Arizona State University, Board of Regents; The University of Texas System
    Inventors: Paul K. Westerhoff, Shahnawaz Sinha, Juan Noveron
  • Patent number: 11753381
    Abstract: Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: September 12, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Richard T. Lewis, Matthew Michael Hamilton, William J. Ray, Fernando Alvarez, Dana E. Pfaffinger, Naphtali Reyna, Jason Cross, Suyambu Kesava Vijayan Ramaswamy
  • Patent number: 11751843
    Abstract: An ultrasound transducer probe holder device comprising a support piece; a base connected to the support piece; a cylindrical orifice within the support piece; a housing extending from the orifice and defining a cavity; a sleeve for insertion within the orifice; and an adjustment screw fitted in the housing for contact with the sleeve. The device supports and maintains the position of an ultrasound transducer probe to provide for a hands-free application of the device during different modalities of exercise required to instigate hyperemic conditions while providing x, y, z, positional adjustments of the probe relative to the patient.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: September 12, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Francisco Morales Acuna, Luis A. Ochoa, Alvaro N. Gurovich
  • Patent number: 11744926
    Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: September 5, 2023
    Assignee: Board Of Regents, The University Of Texas System
    Inventors: Sarah Mayes, Christine E. Schmidt
  • Patent number: 11739177
    Abstract: The present disclosure relates to sealed isocyanate resin compositions. The resin compositions may be used for additive manufacturing. One embodiment of the invention includes a photopolymerizable resin for additive manufacturing, the resin comprising: a blocked isocyanate; at least one monomer or oligomer; and a multifunctional nucleophile.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: August 29, 2023
    Assignees: Adaptive 3D Technologies, Board of Regents, The University of Texas System
    Inventors: Benjamin R. Lund, Walter Voit
  • Patent number: 11738119
    Abstract: Antimicrobial catheters and medical devices are provided. In some aspects, a low durometer aliphatic polyether polyurethane may be impregnated with a first antimicrobial agent (e.g., minocycline and rifampin) and coated with a second antimicrobial agent (e.g., chlorhexidine, gendine, or gardine). The antimicrobial catheters may display improved flexibility and resistance to kinking. Methods of producing the antimicrobial catheters are also provided.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: August 29, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Joel Rosenblatt, Issam Raad
  • Patent number: 11738053
    Abstract: The invention relates to a method of treating chronic granulomatous disease through Hematopoietic stem cell (HSC) transplantation. The method comprises the steps of administering stem cell mobilization agent to human such that the target stem cell population migrates from host niches into the subject's blood. The target stem cells are removed from blood and administering the therapeutic stem cells to human and said therapeutic stem cells are engineered to express gp91phox. The steps are repeated multiple times i.e. at least four times. The mobilization agents used in the invention are granulocyte-colony stimulating factor and AMD3100. The method of HSC transplantation is effective in treatment of chronic granulomatous disease.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: August 29, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Senlin Li, Robert A Clark, Cang Chen, Yang Li
  • Patent number: 11737761
    Abstract: Provided herein are methods, compositions, and devices for occluding cavities or passageways in a patient, in particular cavities or passageways in the cardiovascular system of a patient, such as the LAA of a patient's heart. The methods, compositions, and devices can be used to percutaneously occlude the LAA, decreasing the risk of thromboembolic events associated with AF.
    Type: Grant
    Filed: May 26, 2022
    Date of Patent: August 29, 2023
    Assignees: Applied Cardiovascular Solutions, LLC, Board of Regents, The University of Texas System
    Inventors: F. Javier Otero, Joseph J. Beaman, Krishnendu Roy, Andrew Zimbroff
  • Patent number: 11737671
    Abstract: Method and devices are provided for assessing tissue samples from a plurality of tissue sites in a subject using molecular analysis. In certain aspects, devices of the embodiments allow for minimally invasive collection of liquid tissue samples and delivery of the samples for mass spectrometry analysis.
    Type: Grant
    Filed: November 5, 2021
    Date of Patent: August 29, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Livia Schiavinato Eberlin, Thomas Milner, Jialing Zhang, Noah Giese, Nitesh Katta
  • Patent number: 11730979
    Abstract: Provided herein are noninvasive stimulation methods and apparatus for the treatment of injury to tissues using a novel pulsed laser system that combines the benefits of near-infrared laser light and optoacoustic waves. In certain embodiments, short, high-energy laser light pulses generate low intensity ultrasound waves that travel deep into brain tissues to stimulate neural function and treat neurological dysfunctions. In certain embodiments, a patient interface is provided wherein optoacoustic waves are produced by a plurality of optical absorbers overlying all of a plurality of optical fibers while in other embodiments optoacoustic waves are generated both inside the tissue and outside the tissue via a plurality of optical absorbers overlying some but not all of the optical fibers thus enabling an option of varying proportions of optoacoustic waves generated inside and outside of tissue.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: August 22, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Rinat O. Esenaliev, Maria-Adelaide Micci, Donald S. Prough
  • Patent number: 11730801
    Abstract: The present invention discloses a live attenuated strain of Zika virus (ZIKV) having a deletion in the 3? untranslated region (3?UTR) of the viral genome, which may affect viral RNA synthesis and sensitivity to type I interferon inhibition, but may not affect viral RNA translation. The present invention also discloses the use of these live attenuated ZIKV strains in the preparation of ZIKV vaccines and for providing immunoprotection against ZIKV infection and congenital ZIKV syndrome, particularly in pregnant females.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: August 22, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Pei-Yong Shi, Xuping Xie, Chao Shan